Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Radhika Aiyappa‐Maudsley"'
Autor:
Sarah J. Storr, Victoria Hoskin, Radhika Aiyappa‐Maudsley, Abdi Ghaffari, Sonal Varma, Andrew Green, Emad Rakha, Ian O. Ellis, Peter A. Greer, Stewart G. Martin
Publikováno v:
Cancer Medicine, Vol 12, Iss 9, Pp 10908-10916 (2023)
Abstract Introduction The cytoskeletal protein ezrin is upregulated in many cancer types and is strongly associated with poor patient outcome. While the clinical and prognostic value of ezrin has been previously evaluated in breast cancer, most studi
Externí odkaz:
https://doaj.org/article/c970806911ed436fa210b513806aa37c
Autor:
Radhika Aiyappa‐Maudsley, Sarah J Storr, Emad A Rakha, Andrew R Green, Ian O Ellis, Stewart G Martin
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 8, Iss 6, Pp 550-566 (2022)
Abstract The cytochrome P450 family of enzymes metabolise a wide range of compounds and play important roles in breast cancer pathogenesis due to their involvement in estrogen metabolism and the production of carcinogenic metabolites during this proc
Externí odkaz:
https://doaj.org/article/f4475e0c317e43b4a14ddc6ba556ba65
Autor:
Sarah J. Storr, Victoria Hoskin, Radhika Aiyappa‐Maudsley, Abdi Ghaffari, Sonal Varma, Andrew Green, Emad Rakha, Ian O. Ellis, Peter A. Greer, Stewart G. Martin
Publikováno v:
Cancer Medicine. 12:10908-10916
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ec3787d4da1a6724699772ee3c926ec
https://doi.org/10.1002/cam4.5802
https://doi.org/10.1002/cam4.5802
Publikováno v:
Journal of Cellular and Molecular Medicine. 26:4577-4590
KP167 is a novel hypoxia-activated prodrug (HAP), targeting cancer cells via DNA intercalating and alkylating properties. The single agent and radiosensitizing efficacy of KP167 and its parental comparator, AQ4N, were evaluated in 2D and 3D cultures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03b9990ba613f1da39fad4a9593c6826
https://doi.org/10.1111/jcmm.17486
https://doi.org/10.1111/jcmm.17486
Publikováno v:
Neuro-Oncology Advances. 4
Glioblastoma (GBM) is a highly invasive primary brain tumor in adults with a 5-year survival rate of less than 10%. Conventional radiotherapy with photons, along with concurrent and adjuvant temozolomide, is the mainstay for treatment of GBM although
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e514eb967319992207a3343dbb6236f
https://doi.org/10.1093/noajnl/vdac156
https://doi.org/10.1093/noajnl/vdac156